Dipeptidyl peptidase IV inhibitor improves insulin resistance and steatosis in a refractory nonalcoholic fatty liver disease patient: A case report

Case Reports in Gastroenterology

Volumn 6, Issue 2, 2012, Pages 538-544

  Itou, Minoru ^a   Kawaguchi, Takumi ^a   Taniguchi, Eitaro ^a   Oriishi, Tetsuharu ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetes; Dipeptidyl peptidase IV; Glucose intolerance; Incretin; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; SITAGLIPTIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CALORIC INTAKE; CASE REPORT; DIET THERAPY; ECHOGRAPHY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; PRIORITY JOURNAL;

EID: 84866653492     PISSN: None     EISSN: 16620631     Source Type: Journal    
DOI: 10.1159/000341510     Document Type: Article

References (35)

1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G: A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-384.
2. Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S: ASH and NASH. Dig Dis 2011;29:202-210.
3. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J: Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004;10:S69-S73. (Pubitemid 38240104)
4. Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820-1832.
5. Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P: Review article: Hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 2005;22(suppl 2):64-70. (Pubitemid 41564387)
6. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P: The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005;129:113-121. (Pubitemid 41002048)
7. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J: The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology 2011;54:1208-1216.
8. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174. (Pubitemid 32995375)
9. Krakoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, Edelstein SL, Knowler WC: Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) 2010;18:1762-1767.
10. Greenhill C: Metformin, weight loss and NAFLD. Nat Rev Endocrinol 2010;6:296.
11. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J: Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-1184.
12. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307. (Pubitemid 44837778)
13. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011;305:1659-1668.
14. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685.
15. Lovshin JA, Drucker DJ: Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-269.
16. Drucker DJ, Nauck MA: The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705. (Pubitemid 46048557)
17. Burcelin R The incretins: A link between nutrients and well-being. Br J Nutr 2005;93(suppl 1):S147-S156 (Pubitemid 43073418)
18. D'Alessio DA, Sandoval DA, Seeley RJ: New ways in which GLP-1 can regulate glucose homeostasis. J Clin Invest 2005;115:3406-3408. (Pubitemid 43121828)
19. Drucker DJ: Glucagon-like peptides. Diabetes 1998;47:159-169. (Pubitemid 28079969)
20. Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C, Colom A, Uldry M, Rastrelli S, Sabatier E, Godet N, Waget A, Penicaud L, Valet P, Burcelin R: Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 2008;149:4768-4777.
21. Knauf C, Cani PD, Kim DH, Iglesias MA, Chabo C, Waget A, Colom A, Rastrelli S, Delzenne NM, Drucker DJ, Seeley RJ, Burcelin R: Role of central nervous system glucagon-like peptide-1 receptors in enteric glucose sensing. Diabetes 2008;57:2603-2612.
22. Saraceni C, Broderick TL: Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function. Drugs R D 2007;8:145-153. (Pubitemid 46707838)
23. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA: Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010;51:1584-1592.
24. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006;43:173-181. (Pubitemid 43733604)
25. Williams R: Global challenges in liver disease. Hepatology 2006;44:521-526. (Pubitemid 44433707)
26. Kawaguchi T, Shiba N, Maeda T, Matsugaki T, Takano Y, Itou M, Sakata M, Taniguchi E, Nagata K, Sata M: Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and IL-6 levels in patients with NAFLD: A pilot study. J Gastroenterol 2011;46:746-757.
27. Kawaguchi T, Shiba N, Takano Y, Maeda T, Sata M: Hybrid training of voluntary and electrical muscle contractions decreased fasting blood glucose and serum interleukin-6 levels in elderly people: A pilot study. Appl Physiol Nutr Metab 2011;36:276-283.
28. Sood V, Colleran K, Burge MR: Thiazolidinediones: A comparative review of approved uses. Diabetes Technol Ther 2000;2:429-440.
29. Hummler E, Horisberger JD: Genetic disorders of membrane transport. V. The epithelial sodium channel and its implication in human diseases. Am J Physiol 1999;276:G567-G571.
30. Karpushev AV, Levchenko V, Pavlov TS, Lam VY, Vinnakota KC, Vandewalle A, Wakatsuki T, Staruschenko A: Regulation of ENaC expression at the cell surface by Rab11. Biochem Biophys Res Commun 2008;377:521-525.
31. Pavlov TS, Levchenko V, Karpushev AV, Vandewalle A, Staruschenko A: Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel. Mol Pharmacol 2009;76:1333-1340.
32. Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y: Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan. Diabetes Res Clin Pract 2007;76:229-235. (Pubitemid 46400132)
33. Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Raschia MA, Francini F, Massa ML, Flores LE, Rebolledo OR, Gagliardino JJ: Sitagliptin prevents the development of metabolic and hormonal disturbances, increased beta-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond) 2011;120:73-80.
34. Souza-Mello V, Gregorio BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB, Mandarim-de-Lacerda CA: Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond) 2010;119:239-250.
35. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ: Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006;26:1015-1017. (Pubitemid 44323421)